The real value is in the combination drug
The market had anticipated a rise in sales of Sanofi’s diabetes drug Lyxumia, but sales growth has stagnated in the most recent quarter. Sector analyst Thomas Bowers says things have not gone as expected, but adds that the real value lies in a future combination product.
by Viktor Brandt Kærgaard
Quarter-on-quarter sales of diabetes drug Lyxumia, which is developed by Danish biotech Zealand Pharma and marketed by French drug group Sanofi, remained constant in Q1 2014. Sales totaled EUR 5 million for the second quarter running, but it is still too soon to guess about the future, according to Danske Bank’s pharmaceutical sector analyst Thomas Bowers.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Zealand: Betting on more than a dream
For abonnenter
Analyst: Lyxumia sales should take off in 2014
For abonnenter
Analyst: Study enables higher profit in Zealand
For abonnenter
